First CRISPR single-nucleotide edited transgenic mice

The most recent and highly successful CRISPR-Cas9 technique works by cutting around the faulty nucleotide in both strands of the DNA and cuts out a small part of DNA. Conversely, IBS biologists used a variation of the Cas9 protein (nickase Cas9, nCas9) fused with a protein called cytidine deaminase, a.k.a. Base Editor, which is able to substitute one nucleotide into another. In this way, no DNA deletion occurs, but just one nucleotide substitution. These types of deaminases have been developed and tested in cultured cell lines by David Liu's group at Harvard and Keiji Nishda and his colleagues at Kobe University in 2016. The IBS team advanced the technique further by applying it to mouse embryos.

The scientists tested the CRISPR-nCas9-cytidine deaminase fusion in mice by changing a single nucleotide in the dystrophin gene (Dmd) or the tyrosinase gene (Tyr). They were successful in both cases: Embryos with the single nucleotide mutation in the Dmd gene led to mice producing no dystrophin protein in their muscles, and mice with the Tyr mutation showed albino traits. Dystrophin is indeed connected with the muscular dystrophin disease and tyrosinase controls the production of melanine.

Moreover, these single-nucleotide substitutions appeared only in the target position. This is important because it means that only the correct nucleotide is substituted. "We showed here for the first time that programmable deaminases efficiently induced base substitutions in animal embryos, producing mutant mice with disease phenotypes. This is a proof-of-principle experiment. The next goal is to correct a genetic defect in animals. Ultimately, this technique may allow gene correction in human embryos," expressed KIM Jin-Soo, Director of the Center and leading author of this study.